Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. Among authors: mulgaonkar s. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: mulgaonkar s. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H; B251 Study Group. Lorber MI, et al. Among authors: mulgaonkar s. Transplantation. 2005 Jul 27;80(2):244-52. doi: 10.1097/01.tp.0000164352.65613.24. Transplantation. 2005. PMID: 16041270 Clinical Trial.
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.
Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR. Pescovitz MD, et al. Among authors: mulgaonkar s. Br J Clin Pharmacol. 2007 Dec;64(6):758-71. doi: 10.1111/j.1365-2125.2007.02934.x. Epub 2007 Jun 6. Br J Clin Pharmacol. 2007. PMID: 17555465 Free PMC article. Clinical Trial.
Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.
Oppenheimer F, Mulgaonkar S, Ferguson R, Grinyó J, Juarez F, Ostrowski M, Klinger M, Walker R, Torres A, Preiss R, Cremer M, Jardine A; FTY720 2216 Clinical Study Group. Oppenheimer F, et al. Among authors: mulgaonkar s. Transplantation. 2007 Mar 15;83(5):645-8. doi: 10.1097/01.tp.0000253421.18892.b8. Transplantation. 2007. PMID: 17353787
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM; FTY720 Study Group. Tedesco-Silva H, et al. Among authors: mulgaonkar s. Transplantation. 2006 Dec 27;82(12):1689-97. doi: 10.1097/01.tp.0000251718.95622.b3. Transplantation. 2006. PMID: 17198261 Clinical Trial.
60 results